Palettes of vaccines and immunostimulatory monoclonal antibodies for combination

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1507-1509

  Melero, Ignacio ^a,b,d   Martinez Forero, Ivan ^a   Dubrot, Juan ^a   Suarez, Natalia ^b   Palazón, Asis ^a   Chen, Lieping ^c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD134 ANTIGEN; CD134 MONOCLONAL ANTIBODY; CD137 ANTIGEN; CD137 MONOCLONAL ANTIBODY; CD40 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MDX 1106; MONOCLONAL ANTIBODY; PROGRAMMED CELL DEATH 1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHRITIS; CANCER IMMUNIZATION; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR; T LYMPHOCYTE; THYROIDITIS; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; DRUG COMBINATIONS; HUMANS; IMMUNITY; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; NEOPLASMS; T-LYMPHOCYTES;

EID: 63449088194     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2931     Document Type: Short Survey

References (13)

1. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8: 467-77.
2. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated withT-cell exhaustion and disease progression. Nature 2006;443:350-4.
3. Hirano F, Kaneko K,Tamura H, et al. Blockade of B7-1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
4. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood2008;111:3635-43.
5. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
6. Melero I, Hervas-StubbsS,GlennieM,PardollDM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95 -106.
7. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401 -11.
8. Dranoff G, Jaffee E, Lazenby A, et al.Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci U S A 1993;90: 3539-43.
9. Li B,VanRoey M,Wang C, ChenTT, Korman A, Jooss K. Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunothe rapy Providing Therapeutic Benefit to Micewith Established Tumors. Clin Cancer Res 2009;15:1623-34.
10. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapyofB16melanomausinganti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66.
11. Murata S, Ladle BH, Kim PS, et al. O×40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ Tcell tolerance to an endogenoustumorantigen.JImmunol2006;176:974-83.
12. Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007;125:76-87.
13. Hodi FS, Butler M, Oble DA, et al. Immunologicand clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008;105:3005-10.